The future of focal therapy

Two “pro” and “con” commentaries appeared on line this week in the Journal of Urology under the heading “Focal therapy will become standard treatment for localized prostate cancer.” .. READ MORE …

How many current, PSA-detected, localized prostate cancers are really appropriate for focal therapy?

It is well understood that current Western screening and diagnostic processes commonly identify patients with low volume, low Gleason grade prostate cancer tumors (e.g., a single biopsy core with < 10 percent of the core  positive for cancer of Gleason score 3 + 3 = 6). … READ MORE …

The potential of focal therapy: another assessment

For several years, various research teams have been assessing the potential of focal therapy as a means to treat carefully selected men with localized prostate cancer. However, to date, the ability to identify such men with accuracy prior to such treatment is still in question. … READ MORE …

Focal (hemiablative) HIFU in the treatment of localized prostate cancer

To date there have been few data from well-documented, prospective series of patients receiving any form of focal therapy as treatment for localized prostate cancer, and the criteria for the appropriate clinical use of focal therapy are still a matter of considerable debate. … READ MORE …

Clinical “success” and the management of low-risk, localized prostate cancer

Historically, “success” in the treatment of localized prostate cancer was the elimination of all evidence of cancer from the patient’s prostate and other nearby tissues — through radical surgery or radiation therapy of some type. But the increasing acceptance of active surveillance and the evolution of focal forms of therapy have introduced whole new ways of thinking about the “successful” management of low- and even intermediate-risk, localized disease. … READ MORE …

The natural history of low-risk prostate cancer

In a presentation given at the annual meeting of the American Urology Association earlier this year, researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) provided some interesting data on the natural history of prostate cancer in patients initially diagnosed with low-risk disease. … READ MORE …

If you decide to donate your body for prostate cancer research …

… after you pass away, this is the sort of study that you may be able to watch it be used for (always assuming that there is actually a life after death and that you have the ability to observe what happens to your prior “vessel”). … READ MORE …